RecruitingPhase 2NCT05013892
NTS-WBRT in Brain Metastases
Phase II Trial of Normal Tissue Sparing Whole Brain Radiation Therapy (NTS-WBRT) in Patients With Brain Metastases
Sponsor
Massachusetts General Hospital
Enrollment
41 participants
Start Date
Feb 8, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This research is being done to assess the quality of life and symptom burden in participants who receive (normal tissue sparing whole brain radiation therapy (NTS-WBRT). This research study involves: * NTS-WBRT (normal tissue sparing whole brain radiation therapy) * Memantine standard of care drug
Eligibility
Min Age: 18 Years
Inclusion Criteria13
- Any patient with a solid tumor diagnosis and any number of brain metastasis clinically indicated for cranial irradiation with whole brain radiation therapy
- Age ≥ 18
- Karnofsky Performance Status ≥ 70
- Prior stereotactic radiosurgery (SRS) permissible per physician discretion
- Prior craniotomy permissible per physician discretion. Protocol radiation therapy should be initiated ≥2 weeks after craniotomy.
- Prior partial brain radiation therapy permissible if target volume < 50% brain and per physician discretion
- Expectant > 6 months survival
- Ability to understand and the willingness to sign a written informed consent document.
- Fluency in English, able to complete questionnaires and neurocognitive testing
- Ability to undergo MRI with gadolinium examination
- Ability to return for follow-up examinations throughout the course of this study for a maximum of 2 years after radiation treatment completion
- Any prior, concomitant, or post-radiotherapy systemic therapy is permitted at discretion of treating physicians
- Negative pregnancy test for premenopausal women
Exclusion Criteria7
- Leptomeningeal disease (by any one or more of clinical assessment, radiographic assessment, or cerebrospinal fluid study)
- Prior whole brain radiation therapy
- Pre-existing or current use of memantine or other NMDA antagonists
- Known allergy to contrast used in imaging studies and/or inability to have MRI imaging
- Uncontrolled intercurrent illness that could significantly affect baseline cognitive function as determined by the enrolling clinician, such as symptomatic congestive heart failure, unstable angina pectoris, prior CVA, significant uncontrolled epilepsy or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant or unwilling to use appropriate contraception to prevent pregnancy during the time of radiation therapy
- Concurrent participation in an investigational systemic therapy protocol.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
RADIATIONNTS-WBRT (normal tissue sparing whole brain radiation therapy)
Radiation
DRUGMemantine
Capsule, taken orally
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05013892
Related Trials
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
NCT050482121 location
Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.
NCT062388821 location
Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
NCT074817863 locations
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
NCT059876443 locations
Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin
NCT059778031 location